Washington DC Mar 31I just looked at the Mar 31 press release and I guess I hadn't paid much attention to it at the time. I think one poster or more mentioned they were disappointed by the lack of market response.
What finally hit me like a brick in the face is this quote..."RVX-208
decreases Major Adverse Cardiac Events (MACE) in patients with systemic inflammation".
I can't remember who, but I think it was Sanfran or perhaps biotech or bengtpress posted an observation about the change in language common from
RVX as becoming more certain in it's wording as opposed to the past where the wording was more conditional e.g. rvx-208
may...
The quote in their press release above is
absolute. It
sates that it is true that rvx-208 decreases MACE in certain types of patients.
RVX must be extremely confident about this because this is a public statement and is being viewed by shareholders, interested potential shareholders, BP and
potentially at some point stock market regulators! I don't think RVX would make this statement if they could be in violation
of TSX requirements.
That statement reinforces my hope.
On a separate point -
liquidity. - From what I see, on a very approximate basis, there are about 74mm shares outstanding. In my account it shows that the number of "floating shares" is 51mm.
- So, if I assume that, say, 53% is controlled by insiders, family, etc. then that leaves roughly 24,000,000 shares being traded.
- We know where the control is at this stage.
- What are peoples feelings about the liquidity based on 24mm shares?
Cheers
Toinv